Drew Ranieri
Stock Analyst at Morgan Stanley
(1.28)
# 3,344
Out of 4,759 analysts
164
Total ratings
46.07%
Success rate
-13.25%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $5.16 | +16.39% | 4 | Mar 5, 2025 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $77.41 | +29.18% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $379.30 | +17.32% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $16.06 | +18.31% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $23.00 | +17.39% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $8.57 | -6.65% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $21.56 | +2.04% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $11.00 | -27.27% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $10.46 | +52.96% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $0.60 | +818.20% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $18.43 | +106.19% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $68.70 | +39.74% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $15.24 | +70.60% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $229.54 | +28.52% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $139.85 | +100.21% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $9.20 | -45.65% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $36.57 | +91.41% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $518.26 | -42.11% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $5.16
Upside: +16.39%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $77.41
Upside: +29.18%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $379.30
Upside: +17.32%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $16.06
Upside: +18.31%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $23.00
Upside: +17.39%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $8.57
Upside: -6.65%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $21.56
Upside: +2.04%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $11.00
Upside: -27.27%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $10.46
Upside: +52.96%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $0.60
Upside: +818.20%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $18.43
Upside: +106.19%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $68.70
Upside: +39.74%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $15.24
Upside: +70.60%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $229.54
Upside: +28.52%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $139.85
Upside: +100.21%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $9.20
Upside: -45.65%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $36.57
Upside: +91.41%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $518.26
Upside: -42.11%